20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) plays a key role in cancer progression, including angiogenesis, differentiation, and migration.
• Targeting EGFR is a validated strategy for treating non-small cell lung cancer (NSCLC), pancreatic cancer, and glioblastoma.
• First, second, and third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown therapeutic efficacy.

Purpose of the Study:

• To review breakthroughs in EGFR-targeted cancer therapy over the past 20 years.
• To discuss strategies for overcoming intrinsic and acquired resistance to EGFR inhibitors.
• To highlight new challenges, limitations, and future directions in developing novel EGFR-targeted therapeutics.

Main Methods:

• Comprehensive literature review of research on EGFR inhibitors and resistance mechanisms.
• Analysis of recent advancements in overcoming chemo-resistance.
• Exploration of emerging therapeutic modalities beyond traditional TKIs.

Main Results:

• Significant progress has been made in understanding EGFR mutations and resistance mechanisms.
• Various strategies are being developed to circumvent resistance, including novel inhibitor generations and alternative therapeutic approaches.
• Emerging therapies like fourth-generation EGFR-TKIs, peptides, nanobodies, and PROTACs show promise.

Conclusions:

• Despite advances, drug resistance remains a major challenge in EGFR-targeted cancer therapy.
• Continued research into novel inhibitors and combination strategies is essential.
• Future directions include developing next-generation EGFR inhibitors and exploring innovative therapeutic modalities like PROTACs for improved patient outcomes.